Enterprise Value to EBITDA Ratio: NAYA Biosciences (NAYA)
Biotech success is based on the results of primary antibody tests and the influx of investment capital. NAYA Biosciences is striving to expand its NY-303 oncology pipeline to capture the liver cancer treatment niche. However, geopolitical tensions and sanctions are hindering global scientific exchange. The company's historical EV/EBITDA level demonstrates volatility, where represents the latest metric reading.
nayabiosciences.com - analytical breakdowns and key metrics (NAYA)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity NAYA Biosciences|NAYA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital NAYA Biosciences Inc.|NAYA - Company Aggregate Debts|Debt to Book Value NAYA Biosciences Corp|NAYA - Long-Term Debt|Company Short-Term Debts NAYA Biosciences|Quick Liquidity Indicator nayabiosciences.com
- business earnings and investment ratios data:
NAYA - Final Profit|Projected Future Earnings NAYA Biosciences|NAYA - Price to Earnings Ratio|Forward P/E Multiple NAYA Biosciences|NAYA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NAYA Biosciences Corp|NAYA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months NAYA Biosciences|NAYA - Net earnings per share for the last four quarters|Quarterly EPS earnings growth nayabiosciences.com|NAYA - Net earnings per share growth this year|Earnings growth forecast for next year NAYA Biosciences
Fundamental company analysis:NAYA Bio (NAYA)
The development of NAYA Biosciences is focused on high-risk R&D projects and raising capital for antibody clinical trials. An analysis of the EV/EBITDA dynamics for this capital-intensive company at the current value of allows for a correlation between the total enterprise value and operating profitability before depreciation and interest. This multiple measures the payback period of assets including debt, determining the degree of undervaluation or the financial vulnerability of the issuer during the early stages of commercialization.
Competitor analysis
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc. (ERAS)|delcath.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|EV/EBITDA Multiple Aura Biosciences Inc AURA|CADL: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Accuray, Inc.|SLS: EV/EBITDA Multiple|actuatetherapeutics.com (ACTU) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CTOR|HURA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TARA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FATE (Fate Pharma)|EV/EBITDA Multiple WHWK (Aadi Bioscience)|Total Company Value to Operating Income Before Depreciation Ratio TScan Therapeutics Inc (TCRX)|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA XBiotech Inc.|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OSTX - Total Company Value to Operating Income Before Depreciation Ratio|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Artiva (ARTV)|EV/EBITDA Multiple ANL|Total Company Value to Operating Income Before Depreciation Ratio Veru Inc|EV/EBITDA Multiple TPST (Tempest Tx)|Xilio Therapeutics Inc (XLO) - Company Value to EBITDA|RENB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MURA (Mural Oncology plc) - Enterprise Value to Operating Income Before Depreciation|KAPA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio OnKure Therapeutics|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|Company Value to EBITDA Curis Corp CRIS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apollomics, Inc. (APLM)|Total Company Value to Operating Income Before Depreciation Ratio tharimmune.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Advanced Biomed ADVB|GNPX: Enterprise Value to Operating Income Before Depreciation|Calidi Bio - EV/EBITDA Multiple|SBFM - EV/EBITDA Multiple|XBIO (xeneticbio.com) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA salariuspharma.com (SLRX)|PPBT (Purple Biotech Ltd.) - EV/EBITDA Multiple|EV/EBITDA Multiple AON|EV/EBITDA Multiple BGNE|Enterprise Value to EBITDA Ratio Checkpoint Therapeutics Inc CKPT|EV/EBITDA Multiple ELEV (Elevation Oncology)|EV/EBITDA Multiple iCAD Inc. ICAD|IKNA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NTBL (Notable Labs Ltd) - Enterprise Value to Operating Income Before Depreciation|VIRX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio MorphoSys Corporation|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
